伏诺拉生替代质子泵抑制剂治疗幽门螺杆菌感染的疗效分析  

作　　者：张条条 季夏薇 卢光荣[1] 杨守醒 

机构地区：[1]温州医科大学附属第二医院,325000

出　　处：《浙江临床医学》2025年第1期59-61,共3页Zhejiang Clinical Medical Journal

基　　金：温州市基础性科研项目(Y20220330)。

摘　　要：目的探讨伏诺拉生替代质子泵抑制剂在提高幽门螺杆菌根除率的有效性。方法选择2022年1月至2023年6月在本院确诊的427例幽门螺杆菌感染患者,分为观察组(220例)及对照组(207例)。观察组治疗方案为阿莫西林1.0 g,2次/d,克拉霉素500 mg,2次/d,伏诺拉生片20 mg,1次/d,胶体果胶铋200 mg,2次/d。对照组治疗方案为阿莫西林1.0 g,2次/d,克拉霉素500 mg,2次/d,艾司奥美拉唑镁肠溶片20 mg,2次/d,胶体果胶铋200 mg,2次/d。两组疗程均为14 d。治疗结束后4周,通过13C尿素呼气试验复查,比较两组幽门螺杆菌根除率。结果观察组按意向治疗(ITT)根除率为75%,对照组为73.4%,两组比较差异有统计学意义(P=0.028)。按方案分析(PP)的根除率,观察组为87.9%,对照组为94.8%,差异有统计学意义(P=0.021)。观察组和对照组的不良反应发生率分别为7.27%和5.31%,两组间差异无统计学意义(P>0.05)。结论伏诺拉生铋剂的四联方案在根除幽门螺杆菌方面有效。Objective To explore the effectiveness of vonoprazan as a substitute for proton pump inhibitors(PPIs)in improving the eradication rate of Helicobacter pylori(H.pylori).Methods A total of 427 patients with H.pylori infection diagnosed from January 2022 to June 2023 at our hospital were randomly divided into an experimental group(220 cases)and a control group(207 cases).The experimental group received a treatment regimen of amoxicillin 1.0 g,twice daily,clarithromycin 500 mg,twice daily,vonoprazan fumarate tablets 20 mg,once daily,and colloidal bismuth pectin 200 mg,twice daily.The control group received a treatment regimen of amoxicillin 1.0 g,twice daily,clarithromycin 500 mg,twice daily,esomeprazole magnesium enteric-coated tablets 20 mg,twice daily,and colloidal bismuth pectin 200 mg,twice daily.The treatment duration for both groups was 14 days.Four weeks after the end of treatment,the H.pylori eradication rate was compared between the two groups by 13C urea breath test.Results The intention-to-treat(ITT)eradication rate in the experimental group was 75%,and in the control group,it was 73.4%,with a statistically significant difference between the two groups(P=0.028).The per-protocol(PP)eradication rate was 87.9%in the experimental group and 94.8%in the control group,with a statistically significant difference(P=0.021).The incidence of adverse reactions in the experimental and control groups was 7.27%and 5.31%,respectively,with no statistically significant difference between the two groups(P>0.05).Conclusion The quadruple therapy regimen of vonoprazan and bismuth is effective in eradicating H.pylori.

关 键 词：伏诺拉生 四联方案 幽门螺杆菌 根除率 安全性 

分 类 号：R573[医药卫生—消化系统]